30th November 2022 6:30PM GMT - Virtual

The changing landscape of Waldenström’s Macroglobulinemia (WM) in Scotland

‘The changing landscape of Waldenström’s Macroglobulinemia (WM) in Scotland’ was a live virtual meeting.

agenda

Discussion topic	Discussion Lead
Welcome	Dr Pam McKay
The history and background of WM in Scotland	Dr Pam McKay
Current treatments: BSH guidelines	Dr Dima El-Sharkawi
An in-depth look at the ASPEN study	Dr Shirley D’Sa and Dr Roger OwenDr Jaimal Kothari
Practical considerations of BRUKINSA^®▼	Dr Jaimal Kothari
Panel discussion	Dr McKay, Dr El-Sharkawi ad Dr D’Sa
Close	Dr Pam McKay

Recording

The Changing Landscape of WM in Scotland with Dr Pam McKay

Date of preparation: November 2022. 1122-BRU-PRC-067

Current Treatments: BSH Guidelines with Dr Dima El-Sharkawi

Date of preparation: November 2022. 1122-BRU-PRC-097

An In-Depth Look at the ASPEN Study with Dr Roger Owen and Dr Shirley D’Sa

Date of preparation: November 2022. 1122-BRU-PRC-100

Practical Considerations of Brukinsa with Dr Jaimal Kothari

Date of preparation: November 2022. 1122-BRU-PRC-102

Panel Discussion with Dr Pam McKay, Dr Shirley D’Sa and Dr Dima El-Sharkawi

Date of preparation: December 2022. 1122-BRU-PRC-065

Speakers

Dr Pam McKay

Beatson West of Scotland Cancer Centre

Dr McKay is a Consultant Haematologist at the Beatson, West of Scotland Cancer Centre and an Honorary Clinical Associate Professor at the University of Glasgow School of Medicine. She has a specialist interest in lymphoma and is actively involved in lymphoma at a regional and national level. She is currently a member of the NCRI Lymphoma Clinical Studies Group and the high-grade lymphoma and Hodgkin’s lymphoma Clinical Studies Subgroups.

Dr Dima El-Sharkawi

The Royal Marsden NHS Foundation Trust

Dr Dima El-Sharkawi is a haematology consultant at the Royal Marsden Hospital. Her specialist interest is lymphoma, CLL and the mature lymphoid leukaemias. She is clinical lead for the SIHMDS at the Royal Marsden Hospital. She is the lead for the clinical advisory group for WMUK and is an author on the recently published guidelines for the diagnosis and management of Waldenstrom Macroglobulinaemia.

Dr Shirley D’Sa

UCLH Centre for Waldenström’s Macroglobulinaemia (WM)

Shirley D’Sa, MD, FRCP, FRCPath, is a Consultant Haematologist and Clinical Lead for the UCLH Centre for Waldenström’s macroglobulinemia (WM) and Related Conditions, and Honorary Associate Professor at the UCL Cancer Institute. She is also haematological lead in the Joint Neurohaematology Service at the National Hospital for Neurology and Neurosurgery, Queen Square, London with Prof Michael Lunn a specialist in peripheral nerve diseases.

Dr Roger Owen

Leeds Teaching Hospitals NHS Trust

Consultant Haematologist at St. James University Hospital Institute of Oncology in Leeds, UK. He has a special interest in indolent lymphoma including Waldenstroms macroglobulinaemia and marginal zone lymphoma.

Dr Jaimal Kothari

Oxford University Hospitals

Jaimal Kothari is a consultant haematologist based at Oxford University Hospitals and an Honorary Senior Lecturer in Haematology at The University of Oxford. He completed his haematology training at University College London Hospital, and has particular interests in Waldenstroms Macroglobulinaemia and multiple myeloma. He is Chief Investigator for the UK wide WM-Pembro clinical trial, for patients with relapsed WM and a senior author on the recently published BCSH guidelines for WM.

Events